Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

OBJECTIVE: Previous analyses of pooled DISCOVER‐1 and DISCOVER‐2 data through Week 24 showed significantly higher rates of dactylitis resolution in patients treated with guselkumab compared with placebo. Here, we investigate associations between dactylitis resolution and other outcomes through 1 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: McGonagle, Dennis, McInnes, Iain B., Deodhar, Atul, Schett, Georg, Shawi, May, Chakravarty, Soumya D., Kollmeier, Alexa P., Xu, Xie L., Sheng, Shihong, Xu, Stephen, Ritchlin, Christopher T., Rahman, Proton, Mease, Phillip J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100698/
https://www.ncbi.nlm.nih.gov/pubmed/36880890
http://dx.doi.org/10.1002/acr2.11537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100698/
https://www.ncbi.nlm.nih.gov/pubmed/36880890
http://dx.doi.org/10.1002/acr2.11537

Ejemplares similares